Dermavant Sciences Revenue and Competitors

Claim your profile

Phoenix, AZ USA

Location

#1623

Growjo Ranking

Biotech

Industry

Estimated Revenue & Valuation

  • Dermavant Sciences's estimated annual revenue is currently $66.4M per year.(i)
  • Dermavant Sciences received $100.0M in venture funding in August 2018.
  • Dermavant Sciences's estimated revenue per employee is $217,000

Employee Data

  • Dermavant Sciences has 306 Employees.(i)
  • Dermavant Sciences grew their employee count by 229% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$2.2M3525%N/AN/A
#2
$2.6M34-15%$58.2MN/A
#3
$189.1M1220-14%N/AN/A
#4
$5M3219%N/AN/A
#5
$5.4M3521%N/AN/A
#6
$25M16112%N/AN/A
#7
$0.3M4100%N/AN/A
#8
$5.1M333%N/AN/A
#9
$17.7M1396%N/AN/A
#10
$5.4M356%N/AN/A

A Passion for Science and a Commitment to Dermatology Dermavant Sciences is a specialty biopharmaceutical company developing innovative prescription therapies for dermatologic diseases. Dermavant has acquired promising compounds that address unmet therapeutic needs and has rapidly established a robust dermatology R&D pipeline. We are dedicated to realizing the full potential of biomedical research and to developing and commercializing novel first-in-class or best-in-class therapies that improve patients lives. The patient is at the heart of everything we do.

keywords:N/A

N/A

Total Funding

306

Number of Employees

$66.4M

Revenue (est)

229%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Dermavant Sciences News

2022-04-06 - THE SKIN OF COLOR SOCIETY (SOCS) SUCCESSFULLY ...

This year's SOCS Scientific Symposium was co-chaired by Andrew Alexis, MD, ... Beiersdorf, Dermavant Sciences, Ortho Dermatologics, P & G,...

2022-03-22 - Clinical Catch-Up: Moderna COVID-19 Vaccine for Kids and ...

Dermavant Sciences presented new data from the Phase III PSOARING 3 long-term extension study of tapinarof cream for plaque psoriasis in...

2022-03-22 - Dermavant Appoints Nancy Beesley to its Board of Directors

Dermavant Sciences, a subsidiary of Roivant Sciences, is a clinical-stage biopharmaceutical company dedicated to developing and...

2021-06-08 - Dermavant Sciences Raises $200M in Funding

Dermavant Sciences, a Long Beach CA, Durham, NC, and Basel, Switzerland-based biopharmaceutical company which specializes in immunodermatology therapy, raised $200M in funding. In details, the company has entered into: a $160m revenue interest purchase and sale agreement for its investigational ...

2021-03-11 - Dermavant Announces Tapinarof Data Presentation at the Innovations in Dermatology Conference

LONG BEACH, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Mar 11, 2021-- Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, today announced that an abstract containing interim analysis data fr ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$84.2M306-16%N/A
#2
N/A307N/AN/A
#3
$127.8M3084%N/A
#4
$38.5M3083%N/A
#5
$71M3081%N/A

Dermavant Sciences Funding

DateAmountRoundLead InvestorsReference
2018-08-29$100.0MUndisclosedNovaQuest Capital ManagementArticle